GLP-1 Analog - Search News

Roche And Zealand Team Up To Develop Petrelintide

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this deal is a win-win for RHHBY & ZLDPF.

PharmExec · 4h

Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.

Wall Street Journal · 14h

Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.

Reuters · 15h

Roche to develop, commercialize obesity drug with Zealand Pharma

Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.

Medical Marketing & Media4h

Roche strikes $5.3B obesity treatment deal with Zealand Pharma

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Physician's Weekly12h

Peptide-1 Agonist Relieves IBS Pain but Raises Side Effects

The following is a summary of “Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a ...

BioPharma Dive5h

Roche broadens obesity drug plans with $1.65B Zealand deal

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

BioSpace5d

Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com

Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results